Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access

Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…

AI Summary: A compounding pharmacy has taken legal aim at industry giants Eli Lilly and Novo Nordisk, alleging an anti‑competitive scheme designed to restrict access to their blockbuster GLP‑1 therapies. The lawsuit puts the pharmaceutical titans on the defensive as antitrust concerns mix with therapeutic access debates.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Novo Nordisk slashes prices for Ozempic and Wegovy / 6 months

Trump Administration Secures Lower Obesity Drug Prices / 6 months

Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 6 months

GLP‑1 drugs associated with lower addiction risk in large study / 2 months

FDA Removes Suicide Warnings from GLP‑1 Drugs / 4 months

Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 6 months

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage / 2 months